Please assess the completion status of the following clinical trial:

Trial Title: Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start~* Has increase in polyneuropathy disability (PND) score after liver transplant~* Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start~* Has Karnofsky Performance Status (KPS) of ≥70%~* Has vitamin A level greater than or equal to lower limit of normal~Exclusion Criteria:~* Has previously received inotersen or patisiran~* Has clinically significant liver function test abnormalities~* Has known portal hypertension with ascites~* Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m\^2~* Has known leptomeningeal amyloidosis~* Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Has New York Heart Association heart failure classification of \>2~* Is wheelchair bound or bedridden~* Has received organ transplants other than liver transplant~* Will be using another tetramer stabilizer during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patisiran (Type: EXPERIMENTAL): Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.

Based on this trial design, predict the completion outcome and termination type (if applicable).